Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

Genetic Characterisation and Transmission Cycles of *Cryptosporidium* Species Isolated in New Zealand

A thesis presented in partial fulfilment of the requirements of the degree of

Master of Science

in

Microbiology at Massey University, Palmerston North, New Zealand.

James Jeffrey Learmonth 2004

Abstract

Sixty-nine years separated the first observation of *Cryptosporidium* by Tyzzer in 1907 from the realisation in 1976 that this enteric protozoan parasite was pathogenic. It is the third major cause of diarrhoeal disease worldwide causing a self-limiting infection in immuno-competent humans and young vertebrates. As yet there is no antimicrobial agent that combats *Cryptosporidium* so the organism poses a life threatening risk to the immuno-compromised e.g., AIDS patients, patients on immuno-suppressive drugs, chemotherapy or congenital immune deficiencies. By 2000 AD 152 species of mammals had been reported as being infected with *Cryptosporidium* plus 57 reptilian species and many birds and fish.

The advent of AIDS stimulated research into *Cryptosporidium* resulting in the large amount of information now becoming available, however little is known about the genetic characteristics, distribution and transmission cycles of *Cryptosporidium* species that cause human disease in New Zealand. To address these questions 1613 animal faecal samples and 423 human faecal specimens containing *Cryptosporidium* oocysts were collected from throughout New Zealand and examined by the polymerase chain reaction - restriction fragment length polymorphism technique (PCR-RFLP). Indeterminant results were resolved by DNA sequence analysis of the small subunit ribosomal DNA (rDNA).

Only 2.8% of the animal faecal specimens contained oocysts with the vast majority of these being *C. parvum* bovine genotype from calves.

Two regions supplied the majority of human isolates, one rural and one urban. Overall *C. hominis* accounted for 47% of all human isolates with the remaining 53% being *C. parvum* bovine genotype. A difference however, was observed between the *Cryptosporidium* species from rural and urban isolates with *C. hominis* dominant in the urban region while *C. parvum* bovine genotype was prevalent in rural New Zealand. A shift in transmission cycles was detected between seasons with an anthroponotic cycle in autumn and a zoonotic cycle in spring. A novel *Cryptosporidium*, that on DNA sequence analysis showed a close relationship with *C. canis*, was detected in two unrelated children from different regions, illustrating the genetic diversity within this genus.

Acknowledgements

As with any research of this nature and performed over a lengthy period there are many people to acknowledge, most of them inadequately. Those mentioned below played a major part in the completion of this project and hopefully persons not included in these acknowledgements will forgive me for the oversight.

Professor Tim Brown started me on the journey, providing every encouragement before handing over the reins to my supervisor Dr. George Ionas. George supported me with helpful suggestions, gave me the time to carry out the research and continued to secure contracts from the New Zealand Ministry of Health, which enabled me to keep my head above water. Thanks go to past and present members of the Protozoa Research Unit and MicroAquaTech; Liz Keys, Trish McLenachan, Kim Ebbett, Errol Kwan, Anthony Pita and Rebecca Pattison, all of whom endured my black moments and kept on smiling. Kim rolled her sleeves up and helped me sift through many specimens. If Tim started the voyage thanks go to Glenda Shaw who finished it with her own special style of verbal repetitive commands, ordering me to get on and finish writing.

I well remember going to my first lecture in more years then I am willing to admit to, with Liz Keys. It was a DNA Technology lecture given by the inspiration educator Dr. Stowell, who started the lecture with "we will not have to go over this point as we covered it last year" – it was to become a recurring theme. I really wondered at times at what I was doing there, as must have the ever patient Dr. Stowell.

Collection of the human faecal specimens was carried out by a great many medical laboratory scientists from throughout New Zealand but special thanks go to Jan Bird, who at the time worked for MedLab Hamilton and Vicky McKnight from Medical Laboratory Wellington. Karen Cooper of Gribbles Veterinary Pathology diligently collected animal faecal specimens over many months, allowing me access to many potential *Cryptosporidium* hosts that I could not have otherwise examined. To collect positive faecal specimens and send them to the PRU takes a considerable effort when working in a busy diagnostic laboratory and I thank them all. Without Dr. Padraig Duignan I could not have searched through the faecal specimens from his collection of

marine mammals. Positive horse samples came courtesy of Alex Grinberg also from IVABS. Hopefully all the faecal suppliers will have learnt a little more of the nature of *Cryptosporidium* from this work.

The perpetually busy Ina Te Wiata, who coincidentally was working with *Cryptosporidium* in the mid 1970s when the pathogenicity of the organism was being debated, helpfully proofread the thesis. Her many helpful comments were incorporated into this document.

Finally I must thank my family for their support and words of encouragement; Heather who in the early stages of this project provided me with food, drink, time and space in which to work, Richard for his good humour, Andrew for his understanding (having just handed in his own Master's thesis) and Peter who will finally get the computer back so that he may "clock" whichever game is currently all the rage amongst his age group.

Tab	ole of	<u>Contents</u>	AGE
Absti	ract		ii
<u>Ackn</u>	owledge	<u>ments</u>	iii
Table	e of Con	<u>tents</u>	v
<u>List o</u>	of Figure	<u>es</u>	ix
<u>List o</u>	of Tables	5	xi
Chap	oter One	: Detection, Isolation, Viability and Genetic Characterisation	1
1.1	Crypto	osporidium – Background	1
	1.1.1	History	1
	1.1.2	Biology	1
	1.1.3	Taxonomy	2
1.2	Crypto	osporidium Genome	4
	1.2.1	Molecular genetics	4
	1.2.2	Ribosomal gene organisation	5
1.3	Oocys	et Detection	6
	1.3.1	Acid-fast staining	6
	1.3.2	Immunological detection	6
	1.3.3	Polymerase chain reaction (PCR) techniques	7
1.4	Oocys	st Recovery	9
	1.4.1	Flotation techniques	9
	1.4.2	Flow Cytometry	10
	1.4.3	Immunomagnetic separation (IMS)	11
1.5	Viabi	lity	12
	1.5.1	Fluorogenic vital dyes	13
	1.5.2	Tissue culture infectivity	13
	1.5.3	Animal infectivity	14
	1.5.4	Excystation and genetic analysis	14
	1.5.5	Reverse transcription-PCR of messenger RNA	14

1.6 N	Iolecula	r Characte	risation of Cryptosporidium	15
	1.6.1	Nucleic ac	id extraction	15
	1.6.2	Random a	mplified polymorphic DNA analysis	16
	1.6.3	Sequencin	g and/or PCR-restriction fragment length	
		polymorph	nism analysis	16
	1.6.4	Microsate	llites	18
	1.6.5	Single nuc	eleotide polymorphisms	19
	1.6.6	Viral-like	double-stranded RNA	19
1.7 C	bjective	es and App	roaches	20
Char	oter Two	: Material	s and Methods	22
2.1	Collection of Cryptosporidium Oocysts			22
	2.1.1	Oocyst co	llection from dairy farms	22
	2.1.2	Oocyst co	llection from medical diagnostic laboratories	22
	2.1.3	Oocyst co	llection from veterinary diagnostic laboratories	23
2.2	Detec	tection of Cryptosporidium Oocysts		
	2.2.1	Modified	Ziehl-Nelseen's acid-fast stain	24
	2.2.2	Direct im	munofluorescent antibody stain	25
	2.2.3	Differenti	al interference contrast microscopy	27
2.3	Isolat	Isolation of Cryptosporidium Oocysts		
	2.3.1	Oocyst concentration		
	2.3.2	Immunon	nagnetic separation	28
2.4	Extra	traction of Nucleic Acid from Cryptosporidium Oocysts		
	2.4.1	Nucleic acid extraction		30
2.5	PCR Amplification of Cryptosporidium Loci			
	2.5.1	PCR amp	lification of a generic Cryptosporidium locus	31
		2.5.1.1	Purification, quantitation and sequencing	
			of the PCR products	34
	2.5.2	PCR amp	lification of specific Cryptosporidium loci	36
		2.5.2.1	ITS-1 PCR and RFLP	36
		2.5.2.2	18S rDNA PCR and RFLP	39
		2.5.2.3	β-tubulin PCR and RFLP	43
		2.5.2.4	Poly-T PCR and RFLP	45
		2.5.2.5	COWP PCR and RFLP	47

		2.5.2.6 RNR R1 PCR and RFLP	49
	2.5.3	PCR sensitivity of specific Cryptosporidium loci	51
2.6	RT-P	CR of Viral-Like dsRNA	51
	2.6.1	dsRNA purification	51
	2.6.2	dsRNA RT-PCR	52
2.7	Data .	Analysis	56
	2.7.1	Alignment of Cryptosporidium DNA sequences	56
	2.7.2	Phylogenetic analysis of aligned Cryptosporidium	
		DNA sequences	56
	2.7.3	Nucleotide sequence accession numbers	57
Chap	ter 3: F	Results	58
3.1	Comparison of staining techniques		
3.2	Speci	iating/genotyping Cryptosporidium isolates at various loc	i 59
	3.2.1	ITS-1 rDNA PCR-RFLP	60
	3.2.2	18S rDNA PCR-RFLP	65
	3.2.3	β-tubulin PCR-RFLP	69
	3.2.4	Additional loci examined	71
3.3	Data	analysis	73
	3.3.1	Cryptosporidium species geographic distribution	73
	3.3.2	Cryptosporidium species seasonality	74
3.4	Crypt	tosporidium species subgenotyping	75
Char	oter 4: I	Discussion	78
4.1	Crypt	tosporidium species isolated from animals	78
4.2	Crypt	tosporidium species isolated from humans	79
4.3	Virus	s-like, small dsRNA sub-genotyping	82
4.4	Sumi	mary and future directions	83

<u>Appendices</u>	85
Appendix A: Abbreviations	85
Appendix B: Sequence data	88
Appendix B (i) Multiple 18S rDNA sequence alignment	88
Appendix B (ii) Multiple viral-like dsRNA sequence alignment	94
Appendix B (iii) 18S rDNA evolutionary genetic distances	97
References	98
Publications	118

- Learmonth, J. J., G. Ionas, A. B. Pita, and R. S. Cowie. 2003. Identification and genetic characterisation of *Giardia* and *Cryptosporidium* strains in humans and dairy cattle in the Waikato region of New Zealand. Water Science and Technology 47:21-26.
- Grinberg, A., L. Oliver, J. J. Learmonth, M. Leyland, W. Roe, and W. Pomroy. 2003. Identification of *Cryptosporidium parvum* "cattle" genotype from a severe outbreak of neonatal foal diarrhoea. The Veterinary Record 153:628-631.
- 3. **Learmonth, J. J.,** G. Ionas, K. A. Ebbett, and E. S. Kwan. 2004. Genetic Characterization and Transmission Cycles of *Cryptosporidium* Species Isolated from Humans in New Zealand. Appl. Environ. Microbiol. **70:**3973-3978.

List of Figures

Figure 1.	Coupling of biotinylated <i>Cryptosporidium</i> monoclonal antibody to streptavidin coated paramagnetic beads.	29
	antibody to streptavidin coated paramagnetic beads.	49
Figure 2.	DFA (A) and modified ZN (B) of the same Cryptosporidium	
	positive faecal sample at 640X magnification.	58
Figure 3.	Normaski DIC photomicrograph of viable C. hominis	
	oocysts after IMS isolation. 800X magnification.	59
Figure 4.	C. parvum KSU-1 (bovine genotype) and C. hominis	
	GenBank AF 090312 aligned partial rRNA gene sequences.	61
Figure 5.	ITS-1 rDNA PCR of human and bovine faecal	
	Cryptosporidium isolates.	62
Figure 6.	PCR-RFLP gel of ITS-1 rDNA digested with Dra1.	63
Figure 7.	C. hominis [GenBank AF108865] and C. parvum bovine	
8	genotype [GenBank AF 108864] aligned 18S rDNA	
	gene sequences.	66
Figure 8.	18S rDNA PCR of human and bovine Cryptosporidium isolates.	67
Figure 9.	Cryptosporidium species diagnosis by Vsp1 (A) and Ssp1	
	(B) endonuclease restriction digestion of nested PCR 18S rDNA.	67
Figure 10.	Multiple DNA sequence alignment, including the novel	
	isolates 2683 and 2893, through a polymorphic region of	
	the Cryptosporidium 18S rDNA.	68
Figure 11.	Neighbour-joining tree analysis of Cryptosporidium	
	18S rDNA, showing the phylogenetic relationship of New	
	Zealand isolates to Cryptosporidium species retrieved	
	from GenBank.	70

Figure 12.	PCR-RFLP gels of β-tubulin, Poly T, RNR and COWP loci.	72
Figure 13.	Seasonal changes in the transmission cycle of <i>Cryptosporidium sp.</i> isolated from humans.	75
Figure 14.	RT-PCR of the dsRNA from three Cryptosporidium isolates.	76
Figure 15.	Phylogenetic tree inferred by neighbour joining analysis of dsRNA nucleotide sequences.	77
Figure 16.	National monthly numbers of cryptosporidiosis cases notified to the New Zealand Ministry of Health since	0.4
	July 1996	81

<u>List of Tables</u>

Table 1.	Described species of Cryptosporidium.	3
Table 2.	Recovery efficiency of the USEPA and IMS methods.	10
Table 3.	Length and percentage AT richness of the ITS-1 and ITS-2 rDNA regions of <i>Cryptosporidium</i> isolates from different hosts.	17
Table 4.	Amplicon lengths and <i>Dra1</i> restriction fragment sizes for the ITS-1 region of <i>Cryptosporidium</i> isolates from different hosts.	18
Table 5.	Medical diagnostic laboratories participating in a nationwide survey of <i>Cryptosporidium</i> species infecting humans in New Zealand.	23
Table 6.	Veterinary and animal diagnostic laboratories which referred specimens for <i>Cryptosporidium</i> species detection.	24
Table 7.	PCR sensitivity at six different loci.	60
Table 8.	Total number of faecal samples tested by DFA for the presence of <i>Cryptosporidium</i> oocysts from various hosts. Positive samples were speciated by ITS-1 PCR-RFLP.	64
Table 9.	Total number of faecal samples tested by DFA for the presence of C ryptosporidium oocysts from various hosts. Positive samples were speciated by either 18S rDNA PCR-RFLP and direct sequencing or β -tubulin PCR-RFLP.	71
Table 10.	Restriction endonuclease digestion fragment sizes (bp) at six loci.	73
Table 11.	Geographic distribution of <i>Cryptosporidium</i> species from New Zealand human isolates.	74